日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线治疗EGFR突变型非小细胞肺癌患者,比较奥莫替尼(EGFR酪氨酸激酶抑制剂)联合阿帕替尼(VEGFR抑制剂)与奥莫替尼单药治疗的疗效:一项随机、多中心、II期临床试验

Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma

在透明细胞肾细胞癌中,NF1/2 突变预示着基于免疫检查点抑制剂的疗法比 VEGFR/mTOR 抑制剂更能带来获益。

Sun, Yi; Cheng, Qiang; Zhou, Qiaoxia; Xu, Yu; Wang, Guoqiang; Xu, Chunwei; Wang, Wenxian; Cai, Shangli; Chen, Wenzheng

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study

探索多组学液体活检方法在多种癌症早期检测中的应用:PROMISE 研究

Duan, Jianchun; Gao, Qiang; Wang, Zhijie; Xu, Jiachen; Zhang, Yuzi; Wang, Yanan; Yang, Xi; Zhang, Lei; Xu, Yu; Zhou, Qiaoxia; Yang, Bo; Yang, Xingyu; Wang, Guoqiang; Zhao, Jing; Wang, Xuefei; Ge, Di; Tan, Lijie; Chang, Wenju; Xu, Jianmin; Zhou, Pinghong; He, Mengjiang; Song, Yuanlin; Hu, Jie; Lou, Wenhui; Wu, Wenchuan; Shi, Tingyan; Zang, Rongyu; Ji, Yuan; Jiang, Sunfang; Lin, Youpei; Dong, Liangqing; Cai, Shangli; Fan, Jia; Wang, Jie

Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring

围手术期纳武利尤单抗联合化疗治疗局部晚期食管鳞状细胞癌:一项采用循环肿瘤DNA动态监测的随机多中心II期研究

Jiao, Heng; Lin, Siyun; Gu, Jianmin; Jiang, Dongxian; Cui, Peng; Huang, Zhiliang; Fang, Yong; Wang, Hao; Lin, Miao; Tang, Han; Jiang, Tian; Lin, Guangyi; Zhang, Shaoyuan; Yin, Hao; Liang, Fei; Wang, Jingshu; Fan, Xuning; Qiu, Fujun; Yang, Yang; Li, Zhigang; Li, Bin; Xiang, Jiaqing; Leng, Xuefeng; Han, Yongtao; Li, Chengcheng; Ai, Luoyan; Hou, Yingyong; Wang, Guoqiang; Zhang, Zhihong; Cai, Shangli; Liu, Tianshu; Yin, Jun; Tan, Lijie

Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers

肿瘤信息ctDNA指导晚期非小细胞肺癌一线免疫化疗

Fei, Kailun; Zhao, Jie; Xu, Jiachen; Duan, Jianchun; Li, Chengcheng; Xie, Wenchuan; Zhong, Jia; Wang, Guoqiang; Xu, Yu; Sun, Boyang; Wan, Rui; Bai, Hua; Guo, Qinxiang; Guo, Wei; Cai, Shangli; Wang, Zhijie; Wang, Jie

Performance of Liquid Biopsy-Based Multi-Omics Biomarkers for Early Detection of Gynecological Malignancies: A Prospective Study (PERCEIVE-I)

基于液体活检的多组学生物标志物在妇科恶性肿瘤早期检测中的性能:一项前瞻性研究(PERCEIVE-I)

Feng, Zheng; Ge, Huijuan; Wang, Jingshu; Wang, Yanan; Sun, Xiaoran; Yang, Bo; Cao, Siyu; Quan, Chenlian; Guo, Qinhao; Han, Yusheng; Duan, Feidie; Liu, Fang; Zhao, Jing; Wang, Guoqiang; Zhang, Yuzi; Cai, Shangli; Wu, Xiaohua; Wen, Hao

Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers.

利用八种甲基化血浆DNA标记物经济有效地鉴别肝细胞癌与肝硬化或慢性肝炎病毒感染

Yang Tian, Wang Mingda, Wang Nanya, Pan Mingxin, Xu Yu, You Qiancheng, Yao Lanqing, Xu Jiahao, Gu Lihui, Sun Xiaodong, Zhang Lei, Xu Jiayue, Li Bingsi, Wang Guoqiang, Cai Shangli, Lv Guoyue, Shen Feng

ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma

ctDNA可检测新辅助放化疗后的残留病灶,并指导食管鳞状细胞癌的辅助治疗。

Liu, Zhichao; Wang, Guoqiang; Yang, Yang; Su, Yuchen; Zhang, Hong; Liu, Jun; Cui, Peng; Fan, Xuning; Yang, Jinyu; Zhang, Zhihong; Gao, Xing; Chao, Yinkai; Mostert, Bianca; van Lanschot, J Jan B; Wijnhoven, Bas P L; Law, Simon; Li, Chunguang; Cai, Shangli; Li, Zhigang

Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial

信迪利单抗联合化疗一线治疗晚期肺淋巴上皮瘤样癌:II期试验

Lin, Xinqing; Deng, Haiyi; Fang, Nianxin; Chen, Likun; Chen, Rui; Xie, Xiaohong; Xie, Zhanhong; Zhang, Jiexia; Liu, Ming; Liu, Laiyu; Sun, Ni; Wang, Fei; Yang, Yilin; Lv, Xinze; Zhang, Zhou; Cai, Shangli; Hou, Ting; Li, Shiyue; He, Jianxing; Zhou, Chengzhi

A prognostic signature for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌的预后特征

Liu Yincheng, Xue Ningyi, Duan Feidie, Zhao Kunli, Liang Yan, Zhao Jing, Zhang Lei, Xu Yu, Zhang Yuzi, Wang Guoqiang, Cai Shangli, Zeng Tianyu, Wang Shui